These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 17253773)

  • 1. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation.
    Martinez Z; Zhu M; Han S; Fink AL
    Biochemistry; 2007 Feb; 46(7):1868-77. PubMed ID: 17253773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides.
    Di Pasquale E; Fantini J; Chahinian H; Maresca M; Taïeb N; Yahi N
    J Mol Biol; 2010 Mar; 397(1):202-18. PubMed ID: 20114052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of alpha-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR.
    Ramakrishnan M; Jensen PH; Marsh D
    Biochemistry; 2006 Mar; 45(10):3386-95. PubMed ID: 16519533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of novel NBD-GM1 and NBD-GM2 for the transfer activity of GM2-activator protein by a FRET-based assay system.
    Schwarzmann G; Wendeler M; Sandhoff K
    Glycobiology; 2005 Dec; 15(12):1302-11. PubMed ID: 16079415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease.
    Kumar S; Sarkar A; Sundar D
    Biochem Biophys Res Commun; 2009 Sep; 387(2):305-9. PubMed ID: 19580781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-synuclein selectively binds to anionic phospholipids embedded in liquid-disordered domains.
    Stöckl M; Fischer P; Wanker E; Herrmann A
    J Mol Biol; 2008 Feb; 375(5):1394-404. PubMed ID: 18082181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study.
    Bharathi ; Indi SS; Rao KS
    Neurosci Lett; 2007 Sep; 424(2):78-82. PubMed ID: 17714865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helical alpha-synuclein forms highly conductive ion channels.
    Zakharov SD; Hulleman JD; Dutseva EA; Antonenko YN; Rochet JC; Cramer WA
    Biochemistry; 2007 Dec; 46(50):14369-79. PubMed ID: 18031063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of Cu(II) to human alpha-synucleins: comparison of wild type and the point mutations associated with the familial Parkinson's disease.
    Hong L; Simon JD
    J Phys Chem B; 2009 Jul; 113(28):9551-61. PubMed ID: 19548659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: relevance to Parkinson's disease.
    Bharathi ; Rao KS
    Biochem Biophys Res Commun; 2007 Jul; 359(1):115-20. PubMed ID: 17531952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered levels of α-synuclein and sphingolipids in Batten disease lymphoblast cells.
    Kang S; Heo TH; Kim SJ
    Gene; 2014 Apr; 539(2):181-5. PubMed ID: 24534465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formation of a high affinity lipid-binding intermediate during the early aggregation phase of alpha-synuclein.
    Smith DP; Tew DJ; Hill AF; Bottomley SP; Masters CL; Barnham KJ; Cappai R
    Biochemistry; 2008 Feb; 47(5):1425-34. PubMed ID: 18179253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural determinants of PLD2 inhibition by alpha-synuclein.
    Payton JE; Perrin RJ; Woods WS; George JM
    J Mol Biol; 2004 Apr; 337(4):1001-9. PubMed ID: 15033366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant alpha-synuclein.
    Heise H; Celej MS; Becker S; Riedel D; Pelah A; Kumar A; Jovin TM; Baldus M
    J Mol Biol; 2008 Jul; 380(3):444-50. PubMed ID: 18539297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The aggregation and fibrillation of alpha-synuclein.
    Fink AL
    Acc Chem Res; 2006 Sep; 39(9):628-34. PubMed ID: 16981679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
    Koo HJ; Choi MY; Im H
    Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane-bound structure and energetics of alpha-synuclein.
    Mihajlovic M; Lazaridis T
    Proteins; 2008 Feb; 70(3):761-78. PubMed ID: 17729279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GM1 Ganglioside role in the interaction of Alpha-synuclein with lipid membranes: Morphology and structure.
    Perissinotto F; Rondelli V; Parisse P; Tormena N; Zunino A; Almásy L; Merkel DG; Bottyán L; Sajti S; Casalis L
    Biophys Chem; 2019 Dec; 255():106272. PubMed ID: 31698188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the mechanism of internalization of alpha-synuclein into microglia: roles of ganglioside GM1 and lipid raft.
    Park JY; Kim KS; Lee SB; Ryu JS; Chung KC; Choo YK; Jou I; Kim J; Park SM
    J Neurochem; 2009 Jul; 110(1):400-11. PubMed ID: 19457104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isomers of human alpha-synuclein stabilized by disulfide bonds exhibit distinct structural and aggregative properties.
    Jiang C; Chang JY
    Biochemistry; 2007 Jan; 46(2):602-9. PubMed ID: 17209570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.